Is Casi Pharmaceuticals Inc (NASDAQ:CASI) a Buy? The Stock Reported more Sellers

April 20, 2018 - By Hazel Jackson

CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Logo

Investors sentiment increased to 1.9 in 2017 Q4. Its up 0.76, from 1.14 in 2017Q3. It improved, as 3 investors sold CASI Pharmaceuticals, Inc. shares while 7 reduced holdings. 11 funds opened positions while 8 raised stakes. 3.56 million shares or 48.97% more from 2.39 million shares in 2017Q3 were reported.
Wells Fargo & Mn holds 0% of its portfolio in CASI Pharmaceuticals, Inc. (NASDAQ:CASI) for 50 shares. Morgan Stanley stated it has 0% of its portfolio in CASI Pharmaceuticals, Inc. (NASDAQ:CASI). Moors And Cabot Incorporated invested in 24,663 shares. Raymond James Finance Services Advsr Inc holds 0% of its portfolio in CASI Pharmaceuticals, Inc. (NASDAQ:CASI) for 20,090 shares. Perceptive Advisors Ltd owns 83,682 shares. Royal Natl Bank Of Canada has invested 0% of its portfolio in CASI Pharmaceuticals, Inc. (NASDAQ:CASI). Vanguard Gru owns 936,186 shares for 0% of their portfolio. Virtu Lc invested in 12,124 shares or 0% of the stock. Moreover, Barclays Public Ltd has 0% invested in CASI Pharmaceuticals, Inc. (NASDAQ:CASI) for 66,720 shares. Susquehanna Int Llp invested in 0% or 24,541 shares. Deutsche Financial Bank Ag accumulated 1,721 shares. 10,002 were reported by Everett Harris & Communications Ca. Wellington Shields Capital Management Limited Liability Company invested in 0.37% or 725,348 shares. Blackrock reported 0% in CASI Pharmaceuticals, Inc. (NASDAQ:CASI). Citadel Lc accumulated 18,398 shares.

The stock of Casi Pharmaceuticals Inc (NASDAQ:CASI) registered an increase of 7.32% in short interest. CASI’s total short interest was 1.40M shares in April as published by FINRA. Its up 7.32% from 1.30 million shares, reported previously. With 319,200 shares average volume, it will take short sellers 4 days to cover their CASI’s short positions. The short interest to Casi Pharmaceuticals Inc’s float is 5.1%.

The stock increased 0.73% or $0.05 during the last trading session, reaching $6.89. About 438,434 shares traded. CASI Pharmaceuticals, Inc. (NASDAQ:CASI) has risen 181.56% since April 20, 2017 and is uptrending. It has outperformed by 170.01% the S&P500.

CASI Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of therapeutics addressing cancer and other unmet medical needs in China. The company has market cap of $548.73 million. The Company’s lead drug candidate is ENMD-2076, an Aurora A/angiogenic kinase inhibitor, which is in multiple Phase II studies in advanced fibrolamellar carcinoma, triple-negative breast cancer, advanced ovarian clear cell carcinomas, and advanced/metastatic soft tissue sarcoma. It currently has negative earnings. The companyÂ’s late-stage clinical drug candidates, including MARQIBO, a microtubule inhibitor to treat adult patients with philadelphia chromosome-negative acute lymphoblastic leukemia; ZEVALIN injection for intravenous use indicated for the treatment of patients with relapsed or refractory, low-grade, or follicular B-cell non-hodgkinÂ’s lymphoma, as well as for the treatment of patients with previously untreated follicular non-hodgkinÂ’s lymphoma; and EVOMELA, a melphalan hydrochloride for injection primarily for use as a high-dose conditioning treatment prior to hematopoietic progenitor cell transplantation in patients with multiple myeloma.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.